Associated Genetic Biomarkers
MCL1 Amplification is present in 1.08% of AACR GENIE cases, with breast invasive ductal carcinoma, lung adenocarcinoma, bladder urothelial carcinoma, high grade ovarian serous adenocarcinoma, and prostate adenocarcinoma having the greatest prevalence .
MCL1 Amplification serves as an inclusion eligibility criterion in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains MCL1 Amplification as an inclusion criterion, 1 is phase 2 (0 open).
Significance of MCL1 Amplification in Diseases
Malignant Solid Tumor +
MCL1 is altered in 1.11% of malignant solid tumor patients with MCL1 Amplification present in 1.1% of all malignant solid tumor patients .
MCL1 Amplification is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains MCL1 Amplification and malignant solid tumor as inclusion criteria, 1 is phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.